Regeneron Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Regeneron Pharmaceuticals (REGN).

Price Target Range — 6 Quarters

Analyst Consensus — 23 Analysts

18Buy

5Hold

Consensus RatingBuy# Analysts23Avg. Consensus PT$871Upside to Avg. PT-8.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 2, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$1030→$1100
Nov 2, 2026	Wells Fargo	Mohit Bansal	PT Raise	Equal-Weight	$750→$925
Nov 2, 2026	Evercore ISI Group	Cory Kasimov	PT Raise	Outperform	$900→$1075
Nov 2, 2026	Canaccord Genuity	John Newman	PT Raise	Buy	$922→$1175
Nov 2, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$795→$980
Nov 2, 2026	Baird	Brian Skorney	PT Raise	Neutral	$761→$875
Nov 2, 2026	B of A Securities	Tazeen Ahmad	PT Raise	Buy	$908→$1030
Oct 30, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$950→$1050
Oct 30, 2026	Citigroup	Geoff Meacham	PT Raise	Neutral	$740→$825
Oct 28, 2026	Canaccord Genuity	John Newman	PT Raise	Buy	$875→$922
Oct 21, 2026	TD Cowen	Tyler Van Buren	PT Raise	Buy	$960→$980
Oct 19, 2026	Piper Sandler	Biren Amin	PT Raise	Overweight	$854→$865
Oct 15, 2026	UBS	Trung Huynh	Upgrade	Neutral→Buy	$660→$978
Oct 8, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$737→$810
Oct 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$772→$780
Oct 7, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Equal-Weight	$758→$779
Oct 6, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$900→$950
Oct 1, 2026	Jefferies	Akash Tewari	PT Raise	Buy	$870→$930
Oct 1, 2026	Argus Research	Jasper Hellweg	Upgrade	Hold→Buy	$850
Sep 29, 2026	RBC Capital	Brian Abrahams	Maintained	Sector Perform	$737

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1100

Guggenheim analyst Yatin Suneja maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $1030 to $1100.

Benzinga Newsdesk

These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results

Regeneron beat Q3 estimates with EPS up 70% and revenue up 36%; analysts raised price targets to as high as $1,175.

Avi Kapoor

PRO
Wells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $925

Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $750 to $925.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1075

Evercore ISI Group analyst Cory Kasimov maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform and raises the price target from $900 to $1075.

Benzinga Newsdesk

Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday

Analysts upgraded MHK and CRWD, downgraded PFSI, cut ABOS’s target, and raised targets for NRXP, REGN and NTSK.

Avi Kapoor

PRO
Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1175

Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $922 to $1175.

Benzinga Newsdesk

Regeneron Pharmaceuticals Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Regeneron Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1100

These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results

PRO
Wells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $925

PRO
Evercore ISI Group Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1075

Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday

PRO
Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1175

People Also Watch

People Also Watch

Regeneron Pharmaceuticals Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Regeneron Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1100

These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results

PROWells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $925

PROEvercore ISI Group Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1075

Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday

PROCanaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1175

People Also Watch

People Also Watch

PRO
Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1100

PRO
Wells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $925

PRO
Evercore ISI Group Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1075

PRO
Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1175